Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035) is a research paper published in Gynecologic Oncology Reports (2020). On theSindex it has a DataRank of 0. It has been cited 18 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: CA098258
National Cancer Institute
Grant: CA217685
National Cancer Institute
Grant: CA217842
Stand Up To Cancer
Grant: SU2C-AACR-DT22-17
National Institutes of Health
Grant: R35CA197588
Entertainment Industry Foundation
Grant: SU2C-AACR-DT0209
NCI NIH HHS
Grant: P50 CA217685
NCI NIH HHS
Grant: P30 CA013330
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 1P50CA217685-01
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer
National Institutes of Health
Grant: 5R35CA197588-06
Phosphoinositides and Cancer Metabolism
National Institutes of Health
Grant: 7U01CA217842-03
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer
Ovarian Cancer Research Foundation
AbbVie
Prospect Creek Foundation
Breast Cancer Research Foundation
American Association for Cancer Research
Ovarian Cancer Research Fund
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Gateway Foundation
Genentech
V Foundation for Cancer Research
FWCI
0.90
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals